Brief: GSK Says Momelotinib Granted Orphan Drug Designation In US And EU For Vexas Syndrome
Today 07:30
BRIEF-GSK Says Momelotinib Granted Orphan Drug Designation In US And EU For Vexas Syndrome June 12 (Reuters) - GSK plc GSK.L:
MOMELOTINIB ORPHAN DRUG DESIGNATIONS FOR VEXAS
MOMELOTINIB GRANTED ORPHAN DRUG DESIGNATION IN US AND EU FOR VEXAS SYNDROME
INITIATES ATLAS PHASE II/III TRIAL OF MOMELOTINIB IN VEXAS SYNDROME
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on GSK
See all newsBrief: GSK Says Momelotinib Granted Orphan Drug Designation In US And EU For Vexas Syndrome
Director/PDMR Shareholding
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal (updated)
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
Director/PDMR Shareholding